Sapitinib Reverses Anticancer Drug Resistance in Colon Cancer Cells Overexpressing the ABCB1 Transporter.

Sapitinib Reverses Anticancer Drug Resistance in Colon Cancer Cells Overexpressing the ABCB1 Transporter.
复制标题

DOI:
10.3389/fonc.2020.574861
复制
发表时间:
2020
影响因子:
4.7
通讯作者:
Chen ZS
Chen ZS
中科院分区:
医学3区
文献类型:
--
作者:
Gao HL;Gupta P;Cui Q;Ashar YV;Wu ZX;Zeng L;Lei ZN;Teng QX;Ashby CR Jr;Guan Y;Chen ZS

文献摘要

参考文献

被引文献

相似文献

由于ATP结合盒(ABC)转运蛋白的过度表达而产生的多药耐药(MDR)可削弱抗癌药物在患者中的疗效。在这项体外研究中,我们确定了表皮生长因子受体(EFGR)抑制剂saptinib在SW 620和SW 720/Ad 300结肠癌细胞以及过表达ABCB 1转运蛋白的HEK 293/ABCB 1细胞中的逆转功效。Sapitinib显著增加了紫杉醇和多柔比星在ABCB 1过表达细胞中的疗效,而不改变ABCB 1转运蛋白的表达或亚细胞位置。Sapitinib可显著增加[3 H]-紫杉醇在SW 620/AD 300细胞中的蓄积,可能通过刺激ATP酶活性竞争性抑制[3 H]-紫杉醇的摄取。此外,sapitinib抑制耐药多细胞肿瘤球体(MCTS)的生长。对接研究表明,sapitinib与ABCB 1转运蛋白的外排位点通过π-π相互作用和两个氢键相互作用。总之,我们的研究表明,sapitinib克服了肿瘤细胞中ABCB 1转运蛋白介导的MDR。
The efficacy of anti-cancer drugs in patients can be attenuated by the development of multi-drug resistance (MDR) due to ATP-binding cassette (ABC) transporters overexpression. In this in vitro study, we determined the reversal efficacy of the epidermal growth factor receptor (EFGR) inhibitor, saptinib, in SW620 and SW720/Ad300 colon cancer cells and HEK293/ABCB1 cells which overexpress the ABCB1 transporter. Sapitinib significantly increased the efficacy of paclitaxel and doxorubicin in ABCB1 overexpressing cells without altering the expression or the subcellular location of the ABCB1 transporter. Sapitinib significantly increased the accumulation of [3H]-paclitaxel in SW620/AD300 cells probably by stimulating ATPase activity which could competitively inhibit the uptake of [3H]-paclitaxel. Furthermore, sapitinib inhibited the growth of resistant multicellular tumor spheroids (MCTS). The docking study indicated that sapitinib interacted with the efflux site of ABCB1 transporter by π-π interaction and two hydrogen bonds. In conclusion, our study suggests that sapitinib surmounts MDR mediated by ABCB1 transporter in cancer cells.
DOI: 10.1016/j.bcp.2015.12.007
发表时间: 2016-02-01
影响因子: 5.8
作者:
Chufan EE;Kapoor K;Ambudkar SV
通讯作者: Ambudkar SV
DOI: 10.1158/0008-5472.can-08-0499
发表时间: 2008-10-01
期刊: Cancer research
影响因子: 11.2
作者:
Dai CL;Tiwari AK;Wu CP;Su XD;Wang SR;Liu DG;Ashby CR Jr;Huang Y;Robey RW;Liang YJ;Chen LM;Shi CJ;Ambudkar SV;Chen ZS;Fu LW
通讯作者: Fu LW
DOI: 10.1016/j.canlet.2018.10.020
发表时间: 2019-02-01
期刊: Cancer letters
影响因子: 9.7
作者:
De Vera AA;Gupta P;Lei Z;Liao D;Narayanan S;Teng Q;Reznik SE;Chen ZS
通讯作者: Chen ZS
DOI: 10.1158/1078-0432.ccr-09-2353
发表时间: 2010-02-15
影响因子: 11.5
作者:
Hickinson, D. Mark;Klinowska, Teresa;Ogilvie, Donald
通讯作者: Ogilvie, Donald
Chk1 抑制剂 MK-8776 恢复 P-糖蛋白过表达癌细胞中化疗药物的敏感性
DOI: 10.3390/ijms20174095
发表时间: 2019-09-01
影响因子: 5.6
作者:
Cui, Qingbin;Cai, Chao-Yun;Chen, Zhe-Sheng
通讯作者: Chen, Zhe-Sheng